Breaking News Instant updates and real-time market news.

IRTC

iRhythm

$81.50

3.21 (4.10%)

07:20
01/11/19
01/11
07:20
01/11/19
07:20

iRhythm price target raised to $90 from $84 at Canaccord

Canaccord analyst Jason Mills raised his price target on iRhythm to $90 from $84 and said it represents one of his top picks for 2019. The analyst believes the company will maintain strong growth and its large competitive moat. He expects improving gross margins, thinks the scaling of its U.S. salesforce should translate to revenue upside, and projects increased market share gains. Mills reiterated his Buy rating on iRhythm shares.

IRTC iRhythm
$81.50

3.21 (4.10%)

09/06/18
CHDN
09/06/18
INITIATION
Target $117
CHDN
Buy
iRhythm initiated with a Buy at Chardan
Chardan analyst Steven Wardell started iRhythm Technologies with a Buy rating and $117 price target. The analyst believes good execution by management can drive 25% upside in the shares over the next 12 months. iRhythm has won strong acceptance from payers and growing adoption from providers while growing share, Wardell tells investors in a research note.
09/06/18
09/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with a Sell at Goldman Sachs. 2. Parker-Hannifin (PH) initiated with an Overweight at Barclays. 3. iRhythm (IRTC) initiated with a Buy at Chardan. 4. Sarepta (SRPT) initiated with an Outperform at Credit Suisse. 5. Xperi (XPER) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
ADAM
09/13/18
NO CHANGE
Target $100
ADAM
Buy
iRhythm weakness on Apple Watch an aggressive buying opportunity, says Canaccord
Canaccord analyst Jason Mills said he would be an aggressive buyer of iRhythm (IRTC) shares on weakness following the announcement of Apple's (AAPL)_next generation Watch Series 4. The analyst believes Apple's new watch will be a potential market expander of Zio, the iRhythm platform that is changing the paradigm in ambulatory ECG monitoring. He believes it could add another 3M tests to the TAM longer term. Mills reiterated his Buy rating and raised his price target to $100 from $93 on iRhythm shares.
09/13/18
JPMS
09/13/18
NO CHANGE
JPMS
Overweight
iRhythm selloff on Apple Watch a buying opportunity, says JPMorgan
JPMorgan analyst Robbie Marcus recommends investors use yesterday's weakness in shares of iRhythm Technologies (IRTC) as a buying opportunity. The stock sold off sharply after Apple (AAPL) announced that its new Watch Series 4 had received FDA approval for a built-in electrocardiogram scanner, Marcus tells investors in a research note. While the headline looks like a "notable headwind" for iRhythm, a closer look at the new device shows that this new feature poses almost no competitive threat to the company's Zio XT or AT offerings, Marcus contends. He does not see Apple turning the Watch into a regulated medical device approved for clinical diagnosis. The Apple Watch is approved for over-the-counter use and is not a continuous monitor, the analyst points out. Marcus believes Apple attaining an approval with a similar label to iRhythm's Zio "would significantly slow the rate of innovation and put the consumer device at the whim of the FDA." Instead, he expects that greater consumer preliminary screening for heart arrhythmias will only expand the number of patients seeking medical diagnosis, which, he feels, would benefit iRhythm. The analyst keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

RDS.A

Royal Dutch Shell

$61.07

0.89 (1.48%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Downgrade
Royal Dutch Shell rating change  »

Royal Dutch Shell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMAC

DiaMedica Therapeutics

$3.50

-0.16 (-4.37%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Hot Stocks
DiaMedica Therapeutics announces publication of paper on KLK1, AIS »

DiaMedica Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.97

2.32 (2.02%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Alexion analyst commentary  »

Credit Suisse sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 04

    Feb

  • 18

    Feb

SMTX

SMTC Corp.

$5.60

0.12 (2.19%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Conference/Events
SMTC Corp. management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TIF

Tiffany

$89.85

4.6 (5.40%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HTHT

Huazhu Group

$34.94

1.94 (5.88%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
Huazhu Group initiated  »

Huazhu Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.97

0.18 (1.41%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
GreenTree Hospitality initiated  »

GreenTree Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.10

-0.135 (-2.58%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Conference/Events
TherapeuticsMD management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

ORTX

Orchard Therapeutics

$13.00

0.2 (1.56%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Hot Stocks
Orchard Therapeutics announces OTL-300 data published »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$62.51

1.99 (3.29%)

07:47
01/22/19
01/22
07:47
01/22/19
07:47
Hot Stocks
Jacobs Engineering awarded $93M contract for California WaterFix program »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 19

    Feb

STT

State Street

$71.19

0.07 (0.10%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$18.49

0.48 (2.67%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Redfin rating change  »

Redfin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$18.21

0.7 (4.00%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Downgrade
GasLog rating change  »

GasLog downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

OFG

OFG Bancorp

$18.14

0.19 (1.06%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Earnings
OFG Bancorp reports Q4 EPS 45c, consensus 42c »

Net income available to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 07

    Feb

  • 27

    Feb

07:40
01/22/19
01/22
07:40
01/22/19
07:40
General news
Treasury Market Outlook: Treasury yields are lower in risk-off trades »

Treasury Market Outlook:…

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:39
01/22/19
01/22
07:39
01/22/19
07:39
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.